ALY688, a short peptide of ADPN, was developed by Allysta Pharmaceutical for the treatment of dry eye disease (DED), generally healthy overweight or obese individuals, and nonalcoholic steatohepatitis (NASH). The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatohepatitis.